Recent Quotes

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-12
REV		(EXPECTED)2021-08-12

Q1 2021		Est.		Actual		Surprise
EPS		-0.310		-0.390		-0.0800
REV		8.330M		2.408M		-5.922M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
CDTX	Cidara Therapeutics	2.16	0.03	1.41%		104.3M

Cidara Therapeutics Frequently Asked Questions

How do I buy Cidara Therapeutics (CDTX) stock?

You can purchase shares of Cidara Therapeutics (NASDAQ: CDTX) through any online brokerage.

View our list of the best stock brokerages.

Who are Cidara Therapeutics's (CDTX) competitors?

Other companies in Cidara Therapeutics’s space includes: PolarityTE (NASDAQ:PTE), Cleveland BioLabs (NASDAQ:CBLI), Celyad Oncology (NASDAQ:CYAD), Lumos Pharma (NASDAQ:LUMO) and Aziyo Biologics (NASDAQ:AZYO).

What is the target price for Cidara Therapeutics (CDTX) stock?

The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by Aegis Capital on March 4, 2021. The analyst firm set a price target for 9.00 expecting CDTX to rise to within 12 months (a possible 316.67% upside). 2 analyst firms have reported ratings in the last year.

Current Stock Price for Cidara Therapeutics (CDTX)?

The stock price for Cidara Therapeutics (NASDAQ: CDTX) is $2.16 last updated Fri Jun 11 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Does Cidara Therapeutics (CDTX) pay a dividend?

There are no upcoming dividends for Cidara Therapeutics.

When is Cidara Therapeutics (NASDAQ:CDTX) reporting earnings?

Cidara Therapeutics’s Q2 earnings are confirmed for after-market on August 12, 2021.

Is Cidara Therapeutics (CDTX) going to split?

There is no upcoming split for Cidara Therapeutics.

What sector and industry does Cidara Therapeutics (CDTX) operate in?

Cidara Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.